When does Auvelity’s loss of exclusivity happen?
Auvelity (dextromethorphan/bupropion) is protected by a mix of patent and regulatory exclusivity protections. “Loss of exclusivity” is usually the point when generic or lower-cost versions can enter the U.S. market if they can work around remaining patent barriers.
DrugPatentWatch.com tracks when exclusivity or patent protections are expected to end for specific brands, which is typically what people mean by “loss of exclusivity.” You can check the specific projected dates for Auvelity there: DrugPatentWatch: Auvelity.
Is Auvelity exclusivity ending because patents expire, or because FDA exclusivity runs out?
Loss of exclusivity can come from either (or both) of these buckets:
- Patent expiration (the main reason biosimilars/generics may be delayed).
- FDA exclusivity (a separate mechanism from patents that can delay approval even if patents are later).
DrugPatentWatch.com is useful because it links the brand to the underlying legal timelines so you can tell whether the “end date” is driven by patent expiry, FDA exclusivity, or both. DrugPatentWatch: Auvelity
What happens right after exclusivity ends?
If Auvelity’s exclusivity protections are gone and there is no still-active, blocking patent, a generic applicant may be able to seek approval and commercial launch.
Even after an exclusivity date passes, generics often face continued delays from:
- Remaining patents listed in the Orange Book for Auvelity.
- Patent litigation that can trigger automatic stays in some cases.
To understand which scenario applies to Auvelity, you need the specific patent/exclusivity items tied to the brand—again, where DrugPatentWatch.com is typically the quickest way to map that. DrugPatentWatch: Auvelity
Are there generic or “authorized” versions of Auvelity already?
If exclusivity/patent barriers are still active, you generally will not see full generic competition yet, and the market may rely on brand-only supply.
For the current status (whether any generic has launched or is approved/at-risk), the best starting point is DrugPatentWatch’s live legal/timeline view for Auvelity. DrugPatentWatch: Auvelity
If you meant “NDA exclusivity” vs “patent exclusivity,” which one should you check?
People searching “loss of exclusivity” for a brand sometimes mean:
- FDA marketing exclusivity for the product (based on the approval pathway and exclusivity category).
- Patent exclusivity (i.e., patent term ends).
- Both.
Use the timeline breakdown on DrugPatentWatch.com for Auvelity so you can identify exactly which exclusivity block is expiring and what still remains. DrugPatentWatch: Auvelity
---
Sources
- DrugPatentWatch.com – Auvelity